摘要 |
The present invention relates to pharmaceutical preparations and methods for alleviating and reducing the gastrointestinal toxicity and dysfunction induced by cytoablative therapy, wherein immunomodulatory peptides are employed either alone or in combination with additional therapeutic agents. Also provided are improvements to cytoablative cancer therapy, wherein administration of the subject peptides in conjunction with cytoablative therapy enables the administration of increased maximum tolerated doses of the cytoablative agent(s) for improved efficacy and tumor response.
|